---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Effects of other drugs"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Effects of other drugs. Topics: Concomitant medications that could affect the ability to undergo the neurosurgical procedure; Coagulation and platelet thresholds required before administration; Prior experimental agents, gene therapy, and huntingtin-lowering strategies. 3 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/effects-of-other-drugs"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Effects of other drugs

<a id="heading-2.1.2.9.1"></a>

## 2.1.2.9.1 Effects of Other Drugs on Ifezuntirgene inilparvovec

<a id="topic-2.1.2.9.1-1"></a>

### Concomitant medications that could affect the ability to undergo the neurosurgical procedure

> “Current or recurrent disease, (including pre-existing cardiovascular or pulmonary conditions) infection, or other significant concurrent medical condition or medications that could confound clinical and laboratory evaluations or could affect a participant's safety or their ability to undergo the neurosurgical procedure or comply with the procedures and study visit schedule”

Source: [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493)

<a id="topic-2.1.2.9.1-2"></a>

### Coagulation and platelet thresholds required before administration

> “Platelet count <100,000/mm3”
> “Prothrombin time (PT) >1.2 × ULN”
> “Partial thromboplastin time (PTT) >1.2 × ULN”

Source: [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017)

<a id="topic-2.1.2.9.1-3"></a>

### Prior experimental agents, gene therapy, and huntingtin-lowering strategies

> “Please note that participants will need to be off any other experimental agents for 60 days prior to screening. Previous exposure to gene therapy, huntingtin lowering strategies, or experimental brain surgery are prohibitive to study participation.”

Source: [uniQure Phase I/II clinical trial page](https://www.uniqure.com/programs-pipeline/phase-1-2-clinical-trial-of-amt-130)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
